Merck & Co., Inc.
Holdings as of Jun 30, 2026 · filed Aug 7, 2026
| # | Holding | Value | % Port. | Δ Shares | Change (QoQ) |
|---|---|---|---|---|---|
| 1 | Personalis Inc | $188202236 | 35.75% | — | Held |
| 2 | Moderna Inc | $161642545 | 30.71% | — | Held |
| 3 | Kymera Therapeutics Inc | $88544161 | 16.82% | — | Held |
| 4 | Aktis Oncology Inc | $30710162 | 5.83% | — | Held |
| 5 | Eikon Therapeutics Inc | $21749991 | 4.13% | — | Held |
| 6 | Entrada Therapeutics Inc | $12804692 | 2.43% | — | NEW BUY |
| 7 | Sutro Biopharma Inc | $9042053 | 1.72% | — | NEW BUY |
| 8 | Alector Inc | $7126896 | 1.35% | — | Held |
| 9 | Evaxion Biotech A/S | $3763791 | 0.71% | — | NEW BUY |
| 10 | Viridian Therapeutics Inc | $1716015 | 0.33% | — | Held |
| 11 | Xilio Therapeutics Inc | $1015308 | 0.19% | — | Held |
| 12 | Tuhura Biosciences Inc | $45501 | 0.01% | — | Held |
| 13 | Neuphoria Therapeutics Inc | $43818 | 0.01% | — | Held |
Closed last quarter
Entrada Therapeutics Inc
Sutro Biopharma Inc
Evaxion Biotech A/S
Carisma Therapeutics Inc
Holdings disclosed quarterly to the SEC on Form 13-F and may be up to 45 days old. Values as reported. For research only — not investment advice.